Project Grant R44AI155367
- This National Science Foundation (NSF) Small Business Innovation Research (SBIR) Phase I award to RT Microdx Inc. provides $274,362 to develop a novel molecular diagnostic platform for detecting respiratory diseases like strep throat. The platform aims to provide laboratory-quality accuracy for at-home use by non-healthcare professionals. Key technical objectives include optimizing the sensitivity of the platform's pH-sensitive polymer detection mechanism and ensuring robust performance at...
- This National Science Foundation (NSF) Technology, Innovation, and Partnerships (CFDA 47.084) Project Grant award supports the development of a novel device that can rapidly and automatically extract pathogen DNA from whole blood samples to enable faster diagnosis of sepsis. The $274,858 award to New England Hemolytics, Inc., with a project period from September 1, 2024 to February 28, 2025, will fund the testing and optimization of this technology across common sepsis-causing pathogens. The...
- This federal Project Grant award from the National Science Foundation (NSF) Engineering program (CFDA 47.041) provides $308,000 in funding to Purdue University to develop new diagnostic technologies for detecting the Cyclospora cayetanensis parasite, which often contaminates produce and can lead to disease outbreaks. The key objectives are to: (1) discover DNA aptamers that can specifically recognize and bind to Cyclospora cayetanensis, and (2) integrate these aptamers into a paper-based...
- This National Science Foundation (NSF) Biological Sciences grant award provides $2,225,964 to the Georgia Tech Research Corporation (Georgia Tech) to develop a novel biosensing platform called "protocell communities" that can be used for rapid, low-cost medical diagnostics. The project aims to create a tool that can diagnose medical conditions by detecting and integrating multiple indicator molecules, addressing limitations of single-analyte diagnostics. The protocell technology uses...
- This $788,406 project grant from the National Institutes of Health National Institute of Allergy and Infectious Diseases, under the Allergy and Infectious Diseases Research program (CFDA 93.855), will fund the development of a sensitive, direct reading bioaerosol detection platform to quantify airborne pathogens such as SARS-CoV-2. Aerosol Devices Inc. will integrate their gentle condensation-growth capture sampler, which concentrates intact, viable virus particles into a small liquid volume...
- This National Science Foundation (NSF) Technology, Innovation, and Partnerships (CFDA 47.084) Project Grant award of $275,000 to Quarksen LLC provides funding to develop an affordable, point-of-care diagnostic device for detecting viral and non-viral sexually transmitted infections (STIs) such as chlamydia, gonorrhea, syphilis, HIV, hepatitis C, and trichomoniasis. The project aims to create a device with an array of sensors that can rapidly and accurately detect STI biomarkers from cervical...
- This Project Grant award from the National Science Foundation (CFDA 47.084 - NSF Technology, Innovation, and Partnerships) provides $550,000 to the University of Georgia Research Foundation, Inc. to develop a prototype for rapid diagnosis of foodborne pathogens. The goal is to create a new one-test screening method that can identify bacterial contaminants in food in less than an hour, compared to current multi-step tests that take hours or days. This rapid diagnostic technology is aimed at...
- This National Science Foundation (NSF) Project Grant award for $380,074, awarded on September 1, 2024, aims to develop a platform for instrument-free, easy-to-interpret quantitative analysis of molecular biomarkers. The project will produce a general methodology adaptable to a range of molecular targets, including potential new agents. The key products to be delivered include: A "yes/no" output for quantitative measurement, enabled through stoichiometry and negative cooperativity-based...
- This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), will support the development of a novel universal rapid test for HIV diagnosis. IGE Immunodiagnostics & Therapeutics, LLC, a minority-owned small business, will receive $294,948 to adapt their existing HIV ELISA test into a 5th generation antigen/antibody combination rapid test format. The goal is to create a simple, rapid,...
- The National Science Foundation (NSF), under its Engineering program (CFDA 47.041), awarded a $429,832 Project Grant to the University of Massachusetts (UMass) to develop a novel method for rapid and sensitive detection of nucleic acids such as DNA and RNA. The main objectives of the 5-year project are to: Determine the nanomechanoelectrical transduction principle of nucleic-acid nanostructures tethered to a graphene transistor and oscillating in an electric field. Achieve rapid,...
RAPID, HANDHELD, POINT-OF-CARE STOOL SAMPLE-PREP DEVICE FOR THE EXTRACTION AND DETECTION OF NUCLEIC ACID FROM DIARRHEAL PATHOGENS - ABSTRACT DIARRHEAL DISEASE IS A MAJOR HEALTH ISSUE WORLDWIDE RESULTING IN NEARLY 500,000 DEATHS ANNUALLY IN CHILDREN UNDER 5 YEARS OF AGE. THOSE WHO SURVIVE HAVE HIGHER RISK OF STUNTED GROWTH AND COGNITIVE DEVELOPMENT. IDENTIFICATION OF THE GASTROINTESTINAL (GI) PATHOGENS THAT CAUSE DIARRHEAL DISEASE HELPS GUIDE EFFECTIVE TREATMENT. CURRENTLY, IN THE DEVELOPED WORLD, THIS IS DONE USING MULTIPLEXED PCR LABORATORY TESTS WHICH ARE EXPENSIVE, SLOW AND REQUIRE A SOPHISTICATED HIGH COMPLEXITY LABORATORY. UNFORTUNATELY, SUCH LABORATORY TESTS ARE NOT AVAILABLE IN REMOTE AND RESOURCE LIMITED REGIONS IN THE DEVELOPING WORLD WHERE MORTALITY DUE TO DIARRHEA IS THE HIGHEST. THUS, WE PROPOSE TO DEVELOP AN INTEGRATED, LOW-COST, POINT-OF-CARE (POC) TEST TO IDENTIFY THE GI PATHOGENS THAT CAUSE DIARRHEAL DISEASES. THIS TEST WILL BE USEFUL IN RESOURCE-LIMITED SETTINGS OF THE DEVELOPING WORLD AS WELL AS IN PRIMARY CARE AND URGENT CARE SETTINGS OF THE DEVELOPED WORLD WHERE IT WILL BE USEFUL TO DETECT THE GI PATHOGENS IN REAL TIME, IN THE CLINICIAN'S OFFICE SO THE PATIENT CAN BE TREATED WITH THE RIGHT DRUGS, RIGHT AWAY, WITHOUT LOSS OF PATIENTS TO FOLLOW UP. THE MAJOR PROBLEM WITH DETECTING GASTROINTESTINAL (GI) PATHOGENS IS THE COMPLEXITY OF STOOL SAMPLES, OFTEN FILLED WITH PARTICULATE AND MOLECULES SUCH AS BILE SALTS. SUCH CONTAMINANTS CAN INHIBIT SIGNAL AMPLIFICATION AND DETECTION IF NOT PROPERLY REMOVED FROM THE SAMPLE. IN PREVIOUS SBIR PROJECTS, GODX HAS DEVELOPED SAMPLE PREPARATION CHEMISTRY, DNA AMPLIFICATION AND DETECTION ASSAYS ON LATERAL FLOW PAPER STRIPS FOR A SUITE OF GI PATHOGENS. OUR NEXT STEP IS TO DEVELOP A PATHOGEN DETECTION DEVICE THAT FULLY INTEGRATES SAMPLE PROCESSING AND SIGNAL AMPLIFICATION, WHICH CAN BE USED RAPIDLY AT THE POINT OF CARE (POC). TO ACHIEVE THIS, WE PROPOSE TO DEVELOP A STOOL SAMPLE PREP DEVICE THAT CAN ROBUSTLY PROVIDE VIABLE DNA FOR AMPLIFICATION AND DETECTION ALL WHILE REQUIRING MINIMAL USER ACTION TO DO SO. THE TECHNOLOGY PROPOSED HERE WILL BE ABLE TO EXTRACT AND ENRICH DNA FROM A SWAB OF STOOL IN A MATTER OF MINUTES WITHOUT THE NEED FOR CENTRIFUGES OR PUMPS. IN PHASE 2 OF THIS PROJECT, WE WILL FULLY INTEGRATE THE GODX'S AMPLIFICATION AND DETECTION ASSAYS WITH THE SAMPLE PREP TECHNOLOGY DEVELOPED HERE, PROVIDING A SEAMLESS, MINIMAL STEP POC DEVICE FOR THE DETECTION OF GI PATHOGENS THAT CAUSE DIARRHEAL DISEASES AROUND THE WORLD.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $0 | 1/29/26 | ||
| Not listed | $960.6k | 5/23/24 | ||
| Not listed | $1.1m | 5/30/23 | ||
| Not listed | $1.1m | 5/30/23 |